Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GYNORYLAQ-TM in high-risk or recurrent endometrial carcinoma
NCT07316361Phase 1Enrolling by invitation
- Sponsor
- Biogenea Pharmaceuticals
- Start
- Feb 2026
- Primary completion
- Dec 2029
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GYNORYLAQ in endometrial carcinoma, sponsored by Biogenea Pharmaceuticals. Primary endpoints: Incidence of Treatment-Emergent AEs/SAEs and DLTs, Feasibility of Quantum-Guided Vaccine Manufacturing at 16 weeks and 1 more. Started Feb 2026; status: enrolling by invitation.
02
Drugs
GYNORYLAQ
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT07316361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07316361.